Literature DB >> 3797366

Diclofenac-induced hepatotoxicity.

D Schapira, L Bassan, A M Nahir, Y Scharf.   

Abstract

Two patients developed clinical, biochemical and histopathological signs of a liver hypersensitivity reaction following treatment with diclofenac. Hepatic side effects of this drug are very rare. The relevant literature is reviewed.

Entities:  

Mesh：

Substances：

Year:  1986        PMID： 3797366      PMCID： PMC2418538          DOI： 10.1136/pgmj.62.723.63

Source DB:  PubMed          Journal:  Postgrad Med J        ISSN： 0032-5473            Impact factor:   2.401


  9 in total

1.  A review of spontaneously reported adverse drug reactions with diclofenac sodium (Voltarol).

Authors:  A G Ciucci
Journal:  Rheumatol Rehabil       Date:  1979

2.  Aspirin-induced hepatotoxicity in patients with systemic lupus erythematosus.

Authors:  W E Seaman; K G Ishak; P H Plotz
Journal:  Ann Intern Med       Date:  1974-01       Impact factor: 25.391

3.  Diclofenac hepatitis.

Authors:  A A Dunk; R P Walt; W J Jenkins; S S Sherlock
Journal:  Br Med J (Clin Res Ed)       Date:  1982-05-29

4.  [Hepatitis caused by diclofenac].

Authors:  G Babany; D Pessayre; J P Benhamou
Journal:  Gastroenterol Clin Biol       Date:  1983-03

5.  Fatal hepatitis probably due to indomethacin.

Authors:  W M Kelsey; M Scharyj
Journal:  JAMA       Date:  1967-02-20       Impact factor: 56.272

6.  Jaundice associated with naproxen.

Authors:  R M Victorino; J C Silveira; A Baptista; M C de Moura
Journal:  Postgrad Med J       Date:  1980-05       Impact factor: 2.401

7.  Sulindac hepatotoxicity.

Authors:  S J Whittaker; J N Amar; I R Wanless; J Heathcote
Journal:  Gut       Date:  1982-10       Impact factor: 23.059

8.  Phenylbutazone liver injury: a clinical-pathologic survey of 23 cases and review of the literature.

Authors:  S B Benjamin; K G Ishak; H J Zimmerman; A Grushka
Journal:  Hepatology       Date:  1981 May-Jun       Impact factor: 17.425

9.  The value and results of long-term studies with diclofenac sodium (Voltarol).

Authors:  S N Ciccolunghi; H A Chaudri; B I Schubiger
Journal:  Rheumatol Rehabil       Date:  1979
  9 in total
  8 in total

1.  Renal and hepatic impairment in association with diclofenac administration.

Authors:  P Diggory; R L Golding; R Lancaster
Journal:  Postgrad Med J       Date:  1989-07       Impact factor: 2.401

Review 2.  Metabolism considerations for kinase inhibitors in cancer treatment.

Authors:  Derek R Duckett; Michael D Cameron
Journal:  Expert Opin Drug Metab Toxicol       Date:  2010-10       Impact factor: 4.481

Review 3.  Drug-induced "allergic hepatitis".

Authors:  P Podevin; M Biour
Journal:  Clin Rev Allergy Immunol       Date:  1995       Impact factor: 8.667

Review 4.  Nonsteroidal anti-inflammatory drug-induced hepatic disorders. Incidence and prevention.

Authors:  A V Manoukian; J L Carson
Journal:  Drug Saf       Date:  1996-07       Impact factor: 5.606

5.  Characterization of dasatinib and its structural analogs as CYP3A4 mechanism-based inactivators and the proposed bioactivation pathways.

Authors:  Xiaohai Li; Yuanjun He; Claudia H Ruiz; Marcel Koenig; Michael D Cameron; Tomas Vojkovsky
Journal:  Drug Metab Dispos       Date:  2009-03-12       Impact factor: 3.922

Review 6.  Diclofenac induced hepatitis. 3 cases with features of autoimmune chronic active hepatitis.

Authors:  L J Scully; D Clarke; R J Barr
Journal:  Dig Dis Sci       Date:  1993-04       Impact factor: 3.199

7.  Diclofenac hepatitis.

Authors:  P Purcell; D Henry; G Melville
Journal:  Gut       Date:  1991-11       Impact factor: 23.059

Review 8.  Diclofenac sodium. A reappraisal of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy.

Authors:  P A Todd; E M Sorkin
Journal:  Drugs       Date:  1988-03       Impact factor: 9.546
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.